Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 1/20 | 0.68 |
| ▸ | NPC1 | O15118 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | STAT3 | P40763 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.60 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6671288 | 0.82 | CTSD (0.70) | CTSDNPC1SMN1; SMN2STAT3RAB9A | |
| SCHEMBL353828 | 0.82 | CTSD (0.70) | CTSDNPC1SMN1; SMN2STAT3RAB9A | |
| Hydrochloric Acid SCHEMBL7476155 | 0.81 | CTSD (0.68) | CTSDNPC1SMN1; SMN2STAT3RAB9A | |
| SCHEMBL6239116 | 0.81 | CTSD (0.68) | CTSDNPC1SMN1; SMN2STAT3RAB9A | |
| Hydrochloric Acid SCHEMBL31097029 | 0.81 | CTSD (0.68) | CTSDNPC1SMN1; SMN2STAT3RAB9A | |
| SCHEMBL6504497 | 0.81 | CTSD (0.68) | CTSDNPC1SMN1; SMN2STAT3RAB9A | |
| SCHEMBL13527481 | 0.81 | CTSD (0.73) | CTSDNPC1SMN1; SMN2STAT3RAB9A | |
| SCHEMBL295407 | 0.81 | CTSD (1.00) | CTSDNPC1SMN1; SMN2STAT3RAB9A | |
| SCHEMBL3927357 | 0.81 | CTSD (0.68) | CTSDNPC1SMN1; SMN2STAT3RAB9A | |
| SCHEMBL30349208 | 0.81 | CTSD (1.00) | CTSDNPC1SMN1; SMN2STAT3RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012014127-A1 | 5-LIPOXYGENASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2012-02-02 | — | — | WO | claimed |
| EP-1928465-A1 | BENZODIAZEPINE DERIVATIVES FOR TREATING HEPATITIS C INFECTION | Arrow Therapeutics Limited (GB) | 2008-06-11 | — | — | EP | claimed |
| WO-2007034127-A1 | BENZODIAZEPINE DERIVATIVES FOR TREATING HEPATITIS C INFECTION | ARROW THERAPEUTICS LIMITED (GB) | 2007-03-29 | — | — | WO | claimed |
| WO-2025078808-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2025-04-17 | — | — | WO | disclosed |
| WO-2023165570-A1 | CYCLOALKYL OR HETEROCYCLYL SUBSTITUTED HETEROARYL COMPOUND, AND COMPOSITION AND USE THEREOF | 深圳市塔吉瑞生物医药有限公司 | 2023-09-07 | — | — | WO | disclosed |
| US-20230192691-A1 | HETEROCYCLIC COMPOUNDS AS BTK INHIBITORS | BEIJING INNOCARE PHARMA TECH CO LTD (CN) | 2023-06-22 | — | — | US | disclosed |
| US-11618753-B2 | Aminopyrrolotriazines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-04-04 | — | — | US | disclosed |
| US-20200347071-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-11-05 | — | — | US | disclosed |
| CN-108473481-A | compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2018-08-31 | — | — | CN | disclosed |
| CN-108431007-A | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | 洛克索肿瘤学股份有限公司 | 2018-08-21 | — | — | CN | disclosed |
| US-20120010207-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
| EP-1951244-A2 | CALCILYTIC COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007062370-A2 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010207-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | CTSD 4015/4885NPC1 1918/4885SMN1; SMN2 282/4885 |
| US-20200347071-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | RIPK1, RIPK2, RIPK4 | CTSD 3155/4885NPC1 3814/4885SMN1; SMN2 4059/4885 |
| US-20230192691-A1 | HETEROCYCLIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LYN | CTSD 3079/4885NPC1 3713/4885SMN1; SMN2 4469/4885 |
| US-11618753-B2 | Aminopyrrolotriazines as kinase inhibitors | RIPK1, RIPK2, RIPK4 | CTSD 3155/4885NPC1 3814/4885SMN1; SMN2 4059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.